Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-22), Gubra AS's 3-1 Month Momentum % is N/A%.
The industry rank for Gubra AS's 3-1 Month Momentum % or its related term are showing as below:
CHIX:GUBRAc's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -7.01 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Gubra AS (CHIX:GUBRAc) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Gubra AS 3-1 Month Momentum % Related Terms
CHIX:GUBRAC vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Gubra AS's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Gubra AS's 3-1 Month Momentum % falls into.
Gubra AS (CHIX:GUBRAc) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (CHIX:GUBRAC) has a 3-1 Month Momentum % of N/A% as of Aug. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gubra AS and its competitors. According to the industry distribution chart, Gubra AS ranks #423 out of 1386 companies in the Biotechnology industry, placing it in the top 30.5%.
Is Gubra AS's 3-1 Month Momentum % too high?
Gubra AS's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Gubra AS ranks #423 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gubra AS has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #423 out of 1386 companies for 3-1 Month Momentum %. This puts Gubra AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gubra AS and its competitors. Gubra AS's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Gubra AS (CHIX:GUBRAC) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is kr176.41, compared to a current price of kr354.50 — trading 101% above its estimated fair value. The current 3-1 Month Momentum % is N/A%. Gubra AS's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Gubra AS (CHIX:GUBRAC), the current 3-1 Month Momentum % is N/A% as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (CHIX:GUBRAC) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be overvalued.
The current stock price of kr354.50 is trading 101% above its estimated GF Value™ of kr176.41.
Key valuation signals for CHIX:GUBRAC:
3-1 Month Momentum %: N/A%
GF Value™: kr176.41 vs. price of kr354.50 (101% above fair value)
No single metric tells the full story. See the CHIX:GUBRAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
68GF Score
Get the complete analysis for CHIX:GUBRAC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GUBRAC has been successfully added to your 
